

Global Circulating Tumour DNA (ctDNA) Testing Market Growth (Status and Outlook) 2026-2032

<https://marketpublishers.com/r/G85406982B78EN.html>

Date: May 2026

Pages: 121

Price: US\$ 3,660.00 (Single User License)

ID: G85406982B78EN

Abstracts

The global Circulating Tumour DNA (ctDNA) Testing market size is predicted to grow from US\$ million in 2025 to US\$ million in 2032; it is expected to grow at a CAGR of % from 2026 to 2032.

Circulating tumor DNA (ctDNA) is found in the bloodstream and refers to DNA that comes from cancerous cells and tumors. Most DNA is inside a cell's nucleus. As a tumor grows, cells die and are replaced by new ones. The dead cells get broken down and their contents, including DNA, are released into the bloodstream. ctDNA are small pieces of DNA, usually comprising fewer than 200 building blocks (nucleotides) in length. The quantity of ctDNA varies among individuals and depends on the type of tumor, its location, and for cancerous tumors, the cancer stage. Circulating-tumor DNA (ctDNA) refers to fragments of DNA derived from tumor cells and circulating in the blood together with cell-free DNA from other sources. Circulating tumor DNA (ctDNA) analyses are minimally invasive and accessible for risk stratification or treatment response monitoring of cancer patients. Compared to tumor biopsy analysis, they are not only less invasive, but also provide a more representative picture, allowing capturing both tumor heterogeneity and multiple tumor sites.

United States market for Circulating Tumour DNA (ctDNA) Testing is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Circulating Tumour DNA (ctDNA) Testing is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Circulating Tumour DNA (ctDNA) Testing is estimated to increase

from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Circulating Tumour DNA (ctDNA) Testing players cover Nexomics, Roche, ORIOMICS, Signatera, Illumina, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LPI (LP Information)' newest research report, the 'Circulating Tumour DNA (ctDNA) Testing Industry Forecast' looks at past sales and reviews total world Circulating Tumour DNA (ctDNA) Testing sales in 2025, providing a comprehensive analysis by region and market sector of projected Circulating Tumour DNA (ctDNA) Testing sales for 2026 through 2032. With Circulating Tumour DNA (ctDNA) Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Circulating Tumour DNA (ctDNA) Testing industry.

This Insight Report provides a comprehensive analysis of the global Circulating Tumour DNA (ctDNA) Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Circulating Tumour DNA (ctDNA) Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Circulating Tumour DNA (ctDNA) Testing market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Circulating Tumour DNA (ctDNA) Testing and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Circulating Tumour DNA (ctDNA) Testing.

This report presents a comprehensive overview, market shares, and growth opportunities of Circulating Tumour DNA (ctDNA) Testing market by product type, application, key players and key regions and countries.

Segmentation by Type:

Gastric Cancer Methylation Screening

Esophageal Cancer Methylation Screening

Colorectal Cancer Methylation Screening

Lung Cancer Methylation Screening

Liver Cancer Methylation Screening

Other Cancer Screening

Segmentation by Application:

Hospital

Medical Center

Laboratory

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Nexomics

Roche

ORIOMICS

Signatera

Illumina

Sysmex Corporation

Bio-Rad

Biocartis

QIAGEN

GuardantHealth

GSK plc

AstraZeneca

NeoGenomics Laboratories

AmoyDx

Annoroad

Burning Rock Biotech

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Circulating Tumour DNA (ctDNA) Testing Market Size (2021-2032)
- 2.1.2 Circulating Tumour DNA (ctDNA) Testing Market Size CAGR by Region (2021 VS 2025 VS 2032)
- 2.1.3 World Current & Future Analysis for Circulating Tumour DNA (ctDNA) Testing by Country/Region (2021, 2025 & 2032)

2.2 Circulating Tumour DNA (ctDNA) Testing Segment by Type

- 2.2.1 Gastric Cancer Methylation Screening
- 2.2.2 Esophageal Cancer Methylation Screening
- 2.2.3 Colorectal Cancer Methylation Screening
- 2.2.4 Lung Cancer Methylation Screening
- 2.2.5 Liver Cancer Methylation Screening
- 2.2.6 Other Cancer Screening
- 2.2.7 Circulating Tumour DNA (ctDNA) Testing Market Size by Type
 - 2.2.7.1 Circulating Tumour DNA (ctDNA) Testing Market Size CAGR by Type (2021 VS 2025 VS 2032)
 - 2.2.7.2 Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Type (2021-2026)

2.3 Circulating Tumour DNA (ctDNA) Testing Segment by Application

- 2.3.1 Hospital
- 2.3.2 Medical Center
- 2.3.3 Laboratory
- 2.3.4 Circulating Tumour DNA (ctDNA) Testing Market Size by Application
 - 2.3.4.1 Circulating Tumour DNA (ctDNA) Testing Market Size CAGR by Application

(2021 VS 2025 VS 2032)

2.3.4.2 Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Application (2021-2026)

3 CIRCULATING TUMOUR DNA (CTDNA) TESTING MARKET SIZE BY PLAYER

3.1 Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Player

3.1.1 Global Circulating Tumour DNA (ctDNA) Testing Revenue by Player (2021-2026)

3.1.2 Global Circulating Tumour DNA (ctDNA) Testing Revenue Market Share by Player (2021-2026)

3.2 Global Circulating Tumour DNA (ctDNA) Testing Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 CIRCULATING TUMOUR DNA (CTDNA) TESTING BY REGION

4.1 Circulating Tumour DNA (ctDNA) Testing Market Size by Region (2021-2026)

4.2 Global Circulating Tumour DNA (ctDNA) Testing Annual Revenue by Country/Region (2021-2026)

4.3 Americas Circulating Tumour DNA (ctDNA) Testing Market Size Growth (2021-2026)

4.4 APAC Circulating Tumour DNA (ctDNA) Testing Market Size Growth (2021-2026)

4.5 Europe Circulating Tumour DNA (ctDNA) Testing Market Size Growth (2021-2026)

4.6 Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size Growth (2021-2026)

5 AMERICAS

5.1 Americas Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2021-2026)

5.2 Americas Circulating Tumour DNA (ctDNA) Testing Market Size by Type (2021-2026)

5.3 Americas Circulating Tumour DNA (ctDNA) Testing Market Size by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Circulating Tumour DNA (ctDNA) Testing Market Size by Region (2021-2026)

6.2 APAC Circulating Tumour DNA (ctDNA) Testing Market Size by Type (2021-2026)

6.3 APAC Circulating Tumour DNA (ctDNA) Testing Market Size by Application
(2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 EUROPE

7.1 Europe Circulating Tumour DNA (ctDNA) Testing Market Size by Country
(2021-2026)

7.2 Europe Circulating Tumour DNA (ctDNA) Testing Market Size by Type (2021-2026)

7.3 Europe Circulating Tumour DNA (ctDNA) Testing Market Size by Application
(2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Circulating Tumour DNA (ctDNA) Testing by Region
(2021-2026)

8.2 Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size by Type
(2021-2026)

8.3 Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size by
Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 GLOBAL CIRCULATING TUMOUR DNA (CTDNA) TESTING MARKET FORECAST

10.1 Global Circulating Tumour DNA (ctDNA) Testing Forecast by Region (2027-2032)

10.1.1 Global Circulating Tumour DNA (ctDNA) Testing Forecast by Region (2027-2032)

10.1.2 Americas Circulating Tumour DNA (ctDNA) Testing Forecast

10.1.3 APAC Circulating Tumour DNA (ctDNA) Testing Forecast

10.1.4 Europe Circulating Tumour DNA (ctDNA) Testing Forecast

10.1.5 Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Forecast

10.2 Americas Circulating Tumour DNA (ctDNA) Testing Forecast by Country (2027-2032)

10.2.1 United States Market Circulating Tumour DNA (ctDNA) Testing Forecast

10.2.2 Canada Market Circulating Tumour DNA (ctDNA) Testing Forecast

10.2.3 Mexico Market Circulating Tumour DNA (ctDNA) Testing Forecast

10.2.4 Brazil Market Circulating Tumour DNA (ctDNA) Testing Forecast

10.3 APAC Circulating Tumour DNA (ctDNA) Testing Forecast by Region (2027-2032)

10.3.1 China Circulating Tumour DNA (ctDNA) Testing Market Forecast

10.3.2 Japan Market Circulating Tumour DNA (ctDNA) Testing Forecast

10.3.3 Korea Market Circulating Tumour DNA (ctDNA) Testing Forecast

10.3.4 Southeast Asia Market Circulating Tumour DNA (ctDNA) Testing Forecast

10.3.5 India Market Circulating Tumour DNA (ctDNA) Testing Forecast

10.3.6 Australia Market Circulating Tumour DNA (ctDNA) Testing Forecast

10.4 Europe Circulating Tumour DNA (ctDNA) Testing Forecast by Country (2027-2032)

10.4.1 Germany Market Circulating Tumour DNA (ctDNA) Testing Forecast

10.4.2 France Market Circulating Tumour DNA (ctDNA) Testing Forecast

10.4.3 UK Market Circulating Tumour DNA (ctDNA) Testing Forecast

10.4.4 Italy Market Circulating Tumour DNA (ctDNA) Testing Forecast

- 10.4.5 Russia Market Circulating Tumour DNA (ctDNA) Testing Forecast
- 10.5 Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Forecast by Region (2027-2032)
 - 10.5.1 Egypt Market Circulating Tumour DNA (ctDNA) Testing Forecast
 - 10.5.2 South Africa Market Circulating Tumour DNA (ctDNA) Testing Forecast
 - 10.5.3 Israel Market Circulating Tumour DNA (ctDNA) Testing Forecast
 - 10.5.4 Turkey Market Circulating Tumour DNA (ctDNA) Testing Forecast
- 10.6 Global Circulating Tumour DNA (ctDNA) Testing Forecast by Type (2027-2032)
- 10.7 Global Circulating Tumour DNA (ctDNA) Testing Forecast by Application (2027-2032)
 - 10.7.1 GCC Countries Market Circulating Tumour DNA (ctDNA) Testing Forecast

11 KEY PLAYERS ANALYSIS

11.1 Nexomics

- 11.1.1 Nexomics Company Information
- 11.1.2 Nexomics Circulating Tumour DNA (ctDNA) Testing Product Offered
- 11.1.3 Nexomics Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
- 11.1.4 Nexomics Main Business Overview
- 11.1.5 Nexomics Latest Developments

11.2 Roche

- 11.2.1 Roche Company Information
- 11.2.2 Roche Circulating Tumour DNA (ctDNA) Testing Product Offered
- 11.2.3 Roche Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
- 11.2.4 Roche Main Business Overview
- 11.2.5 Roche Latest Developments

11.3 ORIOMICS

- 11.3.1 ORIOMICS Company Information
- 11.3.2 ORIOMICS Circulating Tumour DNA (ctDNA) Testing Product Offered
- 11.3.3 ORIOMICS Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
- 11.3.4 ORIOMICS Main Business Overview
- 11.3.5 ORIOMICS Latest Developments

11.4 Signatera

- 11.4.1 Signatera Company Information
- 11.4.2 Signatera Circulating Tumour DNA (ctDNA) Testing Product Offered
- 11.4.3 Signatera Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin

and Market Share (2021-2026)

11.4.4 Signatera Main Business Overview

11.4.5 Signatera Latest Developments

11.5 Illumina

11.5.1 Illumina Company Information

11.5.2 Illumina Circulating Tumour DNA (ctDNA) Testing Product Offered

11.5.3 Illumina Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)

11.5.4 Illumina Main Business Overview

11.5.5 Illumina Latest Developments

11.6 Sysmex Corporation

11.6.1 Sysmex Corporation Company Information

11.6.2 Sysmex Corporation Circulating Tumour DNA (ctDNA) Testing Product Offered

11.6.3 Sysmex Corporation Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)

11.6.4 Sysmex Corporation Main Business Overview

11.6.5 Sysmex Corporation Latest Developments

11.7 Bio-Rad

11.7.1 Bio-Rad Company Information

11.7.2 Bio-Rad Circulating Tumour DNA (ctDNA) Testing Product Offered

11.7.3 Bio-Rad Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)

11.7.4 Bio-Rad Main Business Overview

11.7.5 Bio-Rad Latest Developments

11.8 Biocartis

11.8.1 Biocartis Company Information

11.8.2 Biocartis Circulating Tumour DNA (ctDNA) Testing Product Offered

11.8.3 Biocartis Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)

11.8.4 Biocartis Main Business Overview

11.8.5 Biocartis Latest Developments

11.9 QIAGEN

11.9.1 QIAGEN Company Information

11.9.2 QIAGEN Circulating Tumour DNA (ctDNA) Testing Product Offered

11.9.3 QIAGEN Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)

11.9.4 QIAGEN Main Business Overview

11.9.5 QIAGEN Latest Developments

11.10 GuardantHealth

- 11.10.1 GuardantHealth Company Information
- 11.10.2 GuardantHealth Circulating Tumour DNA (ctDNA) Testing Product Offered
- 11.10.3 GuardantHealth Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
- 11.10.4 GuardantHealth Main Business Overview
- 11.10.5 GuardantHealth Latest Developments
- 11.11 GSK plc
 - 11.11.1 GSK plc Company Information
 - 11.11.2 GSK plc Circulating Tumour DNA (ctDNA) Testing Product Offered
 - 11.11.3 GSK plc Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 11.11.4 GSK plc Main Business Overview
 - 11.11.5 GSK plc Latest Developments
- 11.12 AstraZeneca
 - 11.12.1 AstraZeneca Company Information
 - 11.12.2 AstraZeneca Circulating Tumour DNA (ctDNA) Testing Product Offered
 - 11.12.3 AstraZeneca Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 11.12.4 AstraZeneca Main Business Overview
 - 11.12.5 AstraZeneca Latest Developments
- 11.13 NeoGenomics Laboratories
 - 11.13.1 NeoGenomics Laboratories Company Information
 - 11.13.2 NeoGenomics Laboratories Circulating Tumour DNA (ctDNA) Testing Product Offered
 - 11.13.3 NeoGenomics Laboratories Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 11.13.4 NeoGenomics Laboratories Main Business Overview
 - 11.13.5 NeoGenomics Laboratories Latest Developments
- 11.14 AmoyDx
 - 11.14.1 AmoyDx Company Information
 - 11.14.2 AmoyDx Circulating Tumour DNA (ctDNA) Testing Product Offered
 - 11.14.3 AmoyDx Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 11.14.4 AmoyDx Main Business Overview
 - 11.14.5 AmoyDx Latest Developments
- 11.15 Annoroad
 - 11.15.1 Annoroad Company Information
 - 11.15.2 Annoroad Circulating Tumour DNA (ctDNA) Testing Product Offered
 - 11.15.3 Annoroad Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin

and Market Share (2021-2026)

11.15.4 Annoroad Main Business Overview

11.15.5 Annoroad Latest Developments

11.16 Burning Rock Biotech

11.16.1 Burning Rock Biotech Company Information

11.16.2 Burning Rock Biotech Circulating Tumour DNA (ctDNA) Testing Product
Offered

11.16.3 Burning Rock Biotech Circulating Tumour DNA (ctDNA) Testing Revenue,
Gross Margin and Market Share (2021-2026)

11.16.4 Burning Rock Biotech Main Business Overview

11.16.5 Burning Rock Biotech Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Circulating Tumour DNA (ctDNA) Testing Market Size CAGR by Region (2021 VS 2025 VS 2032) & (\$ millions)
- Table 2. Circulating Tumour DNA (ctDNA) Testing Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)
- Table 3. Major Players of Gastric Cancer Methylation Screening
- Table 4. Major Players of Esophageal Cancer Methylation Screening
- Table 5. Major Players of Colorectal Cancer Methylation Screening
- Table 6. Major Players of Lung Cancer Methylation Screening
- Table 7. Major Players of Liver Cancer Methylation Screening
- Table 8. Major Players of Other Cancer Screening
- Table 9. Circulating Tumour DNA (ctDNA) Testing Market Size CAGR by Type (2021 VS 2025 VS 2032) & (\$ millions)
- Table 10. Global Circulating Tumour DNA (ctDNA) Testing Market Size by Type (2021-2026) & (\$ millions)
- Table 11. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Type (2021-2026)
- Table 12. Circulating Tumour DNA (ctDNA) Testing Market Size CAGR by Application (2021 VS 2025 VS 2032) & (\$ millions)
- Table 13. Global Circulating Tumour DNA (ctDNA) Testing Market Size by Application (2021-2026) & (\$ millions)
- Table 14. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Application (2021-2026)
- Table 15. Global Circulating Tumour DNA (ctDNA) Testing Revenue by Player (2021-2026) & (\$ millions)
- Table 16. Global Circulating Tumour DNA (ctDNA) Testing Revenue Market Share by Player (2021-2026)
- Table 17. Circulating Tumour DNA (ctDNA) Testing Key Players Head office and Products Offered
- Table 18. Circulating Tumour DNA (ctDNA) Testing Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
- Table 19. New Products and Potential Entrants
- Table 20. Mergers & Acquisitions, Expansion
- Table 21. Global Circulating Tumour DNA (ctDNA) Testing Market Size by Region (2021-2026) & (\$ millions)
- Table 22. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share

by Region (2021-2026)

Table 23. Global Circulating Tumour DNA (ctDNA) Testing Revenue by Country/Region (2021-2026) & (\$ millions)

Table 24. Global Circulating Tumour DNA (ctDNA) Testing Revenue Market Share by Country/Region (2021-2026)

Table 25. Americas Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2021-2026) & (\$ millions)

Table 26. Americas Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Country (2021-2026)

Table 27. Americas Circulating Tumour DNA (ctDNA) Testing Market Size by Type (2021-2026) & (\$ millions)

Table 28. Americas Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Type (2021-2026)

Table 29. Americas Circulating Tumour DNA (ctDNA) Testing Market Size by Application (2021-2026) & (\$ millions)

Table 30. Americas Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Application (2021-2026)

Table 31. APAC Circulating Tumour DNA (ctDNA) Testing Market Size by Region (2021-2026) & (\$ millions)

Table 32. APAC Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Region (2021-2026)

Table 33. APAC Circulating Tumour DNA (ctDNA) Testing Market Size by Type (2021-2026) & (\$ millions)

Table 34. APAC Circulating Tumour DNA (ctDNA) Testing Market Size by Application (2021-2026) & (\$ millions)

Table 35. Europe Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2021-2026) & (\$ millions)

Table 36. Europe Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Country (2021-2026)

Table 37. Europe Circulating Tumour DNA (ctDNA) Testing Market Size by Type (2021-2026) & (\$ millions)

Table 38. Europe Circulating Tumour DNA (ctDNA) Testing Market Size by Application (2021-2026) & (\$ millions)

Table 39. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size by Region (2021-2026) & (\$ millions)

Table 40. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size by Type (2021-2026) & (\$ millions)

Table 41. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size by Application (2021-2026) & (\$ millions)

Table 42. Key Market Drivers & Growth Opportunities of Circulating Tumour DNA (ctDNA) Testing

Table 43. Key Market Challenges & Risks of Circulating Tumour DNA (ctDNA) Testing

Table 44. Key Industry Trends of Circulating Tumour DNA (ctDNA) Testing

Table 45. Global Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Region (2027-2032) & (\$ millions)

Table 46. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share Forecast by Region (2027-2032)

Table 47. Global Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Type (2027-2032) & (\$ millions)

Table 48. Global Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Application (2027-2032) & (\$ millions)

Table 49. Nexomics Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors

Table 50. Nexomics Circulating Tumour DNA (ctDNA) Testing Product Offered

Table 51. Nexomics Circulating Tumour DNA (ctDNA) Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 52. Nexomics Main Business

Table 53. Nexomics Latest Developments

Table 54. Roche Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors

Table 55. Roche Circulating Tumour DNA (ctDNA) Testing Product Offered

Table 56. Roche Circulating Tumour DNA (ctDNA) Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 57. Roche Main Business

Table 58. Roche Latest Developments

Table 59. ORIOMICS Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors

Table 60. ORIOMICS Circulating Tumour DNA (ctDNA) Testing Product Offered

Table 61. ORIOMICS Circulating Tumour DNA (ctDNA) Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 62. ORIOMICS Main Business

Table 63. ORIOMICS Latest Developments

Table 64. Signatera Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors

Table 65. Signatera Circulating Tumour DNA (ctDNA) Testing Product Offered

Table 66. Signatera Circulating Tumour DNA (ctDNA) Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 67. Signatera Main Business

Table 68. Signatera Latest Developments

Table 69. Illumina Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors

Table 70. Illumina Circulating Tumour DNA (ctDNA) Testing Product Offered

Table 71. Illumina Circulating Tumour DNA (ctDNA) Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 72. Illumina Main Business

Table 73. Illumina Latest Developments

Table 74. Sysmex Corporation Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors

Table 75. Sysmex Corporation Circulating Tumour DNA (ctDNA) Testing Product Offered

Table 76. Sysmex Corporation Circulating Tumour DNA (ctDNA) Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 77. Sysmex Corporation Main Business

Table 78. Sysmex Corporation Latest Developments

Table 79. Bio-Rad Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors

Table 80. Bio-Rad Circulating Tumour DNA (ctDNA) Testing Product Offered

Table 81. Bio-Rad Circulating Tumour DNA (ctDNA) Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 82. Bio-Rad Main Business

Table 83. Bio-Rad Latest Developments

Table 84. Biocartis Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors

Table 85. Biocartis Circulating Tumour DNA (ctDNA) Testing Product Offered

Table 86. Biocartis Circulating Tumour DNA (ctDNA) Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 87. Biocartis Main Business

Table 88. Biocartis Latest Developments

Table 89. QIAGEN Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors

Table 90. QIAGEN Circulating Tumour DNA (ctDNA) Testing Product Offered

Table 91. QIAGEN Circulating Tumour DNA (ctDNA) Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 92. QIAGEN Main Business

Table 93. QIAGEN Latest Developments

Table 94. GuardantHealth Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors

Table 95. GuardantHealth Circulating Tumour DNA (ctDNA) Testing Product Offered

Table 96. GuardantHealth Circulating Tumour DNA (ctDNA) Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 97. GuardantHealth Main Business

Table 98. GuardantHealth Latest Developments

Table 99. GSK plc Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors

Table 100. GSK plc Circulating Tumour DNA (ctDNA) Testing Product Offered

Table 101. GSK plc Circulating Tumour DNA (ctDNA) Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 102. GSK plc Main Business

Table 103. GSK plc Latest Developments

Table 104. AstraZeneca Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors

Table 105. AstraZeneca Circulating Tumour DNA (ctDNA) Testing Product Offered

Table 106. AstraZeneca Circulating Tumour DNA (ctDNA) Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 107. AstraZeneca Main Business

Table 108. AstraZeneca Latest Developments

Table 109. NeoGenomics Laboratories Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors

Table 110. NeoGenomics Laboratories Circulating Tumour DNA (ctDNA) Testing Product Offered

Table 111. NeoGenomics Laboratories Circulating Tumour DNA (ctDNA) Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 112. NeoGenomics Laboratories Main Business

Table 113. NeoGenomics Laboratories Latest Developments

Table 114. AmoyDx Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors

Table 115. AmoyDx Circulating Tumour DNA (ctDNA) Testing Product Offered

Table 116. AmoyDx Circulating Tumour DNA (ctDNA) Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 117. AmoyDx Main Business

Table 118. AmoyDx Latest Developments

Table 119. Annoroad Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors

Table 120. Annoroad Circulating Tumour DNA (ctDNA) Testing Product Offered

Table 121. Annoroad Circulating Tumour DNA (ctDNA) Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 122. Annoroad Main Business

Table 123. Annoroad Latest Developments

Table 124. Burning Rock Biotech Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors

Table 125. Burning Rock Biotech Circulating Tumour DNA (ctDNA) Testing Product Offered

Table 126. Burning Rock Biotech Circulating Tumour DNA (ctDNA) Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 127. Burning Rock Biotech Main Business

Table 128. Burning Rock Biotech Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Circulating Tumour DNA (ctDNA) Testing Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Circulating Tumour DNA (ctDNA) Testing Market Size Growth Rate (2021-2032) (\$ millions)

Figure 6. Circulating Tumour DNA (ctDNA) Testing Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Figure 7. Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Country/Region (2025)

Figure 8. Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Country/Region (2021, 2025 & 2032)

Figure 9. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Type in 2025

Figure 10. Circulating Tumour DNA (ctDNA) Testing in Hospital

Figure 11. Global Circulating Tumour DNA (ctDNA) Testing Market: Hospital (2021-2026) & (\$ millions)

Figure 12. Circulating Tumour DNA (ctDNA) Testing in Medical Center

Figure 13. Global Circulating Tumour DNA (ctDNA) Testing Market: Medical Center (2021-2026) & (\$ millions)

Figure 14. Circulating Tumour DNA (ctDNA) Testing in Laboratory

Figure 15. Global Circulating Tumour DNA (ctDNA) Testing Market: Laboratory (2021-2026) & (\$ millions)

Figure 16. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Application in 2025

Figure 17. Global Circulating Tumour DNA (ctDNA) Testing Revenue Market Share by Player in 2025

Figure 18. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Region (2021-2026)

Figure 19. Americas Circulating Tumour DNA (ctDNA) Testing Market Size 2021-2026 (\$ millions)

Figure 20. APAC Circulating Tumour DNA (ctDNA) Testing Market Size 2021-2026 (\$ millions)

Figure 21. Europe Circulating Tumour DNA (ctDNA) Testing Market Size 2021-2026 (\$ millions)

Figure 22. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size 2021-2026 (\$ millions)

Figure 23. Americas Circulating Tumour DNA (ctDNA) Testing Value Market Share by Country in 2025

Figure 24. United States Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 (\$ millions)

Figure 25. Canada Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 (\$ millions)

Figure 26. Mexico Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 (\$ millions)

Figure 27. Brazil Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 (\$ millions)

Figure 28. APAC Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Region in 2025

Figure 29. APAC Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Type (2021-2026)

Figure 30. APAC Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Application (2021-2026)

Figure 31. China Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 (\$ millions)

Figure 32. Japan Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 (\$ millions)

Figure 33. South Korea Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 (\$ millions)

Figure 34. Southeast Asia Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 (\$ millions)

Figure 35. India Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 (\$ millions)

Figure 36. Australia Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 (\$ millions)

Figure 37. Europe Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Country in 2025

Figure 38. Europe Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Type (2021-2026)

Figure 39. Europe Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Application (2021-2026)

Figure 40. Germany Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 (\$ millions)

Figure 41. France Circulating Tumour DNA (ctDNA) Testing Market Size Growth

2021-2026 (\$ millions)

Figure 42. UK Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 (\$ millions)

Figure 43. Italy Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 (\$ millions)

Figure 44. Russia Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 (\$ millions)

Figure 45. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Region (2021-2026)

Figure 46. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Type (2021-2026)

Figure 47. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Application (2021-2026)

Figure 48. Egypt Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 (\$ millions)

Figure 49. South Africa Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 (\$ millions)

Figure 50. Israel Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 (\$ millions)

Figure 51. Turkey Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 (\$ millions)

Figure 52. GCC Countries Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 (\$ millions)

Figure 53. Americas Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 (\$ millions)

Figure 54. APAC Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 (\$ millions)

Figure 55. Europe Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 (\$ millions)

Figure 56. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 (\$ millions)

Figure 57. United States Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 (\$ millions)

Figure 58. Canada Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 (\$ millions)

Figure 59. Mexico Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 (\$ millions)

Figure 60. Brazil Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 (\$ millions)

Figure 61. China Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 (\$ millions)

Figure 62. Japan Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 (\$ millions)

Figure 63. Korea Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 (\$ millions)

Figure 64. Southeast Asia Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 (\$ millions)

Figure 65. India Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 (\$ millions)

Figure 66. Australia Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 (\$ millions)

Figure 67. Germany Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 (\$ millions)

Figure 68. France Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 (\$ millions)

Figure 69. UK Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 (\$ millions)

Figure 70. Italy Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 (\$ millions)

Figure 71. Russia Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 (\$ millions)

Figure 72. Egypt Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 (\$ millions)

Figure 73. South Africa Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 (\$ millions)

Figure 74. Israel Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 (\$ millions)

Figure 75. Turkey Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 (\$ millions)

Figure 76. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share Forecast by Type (2027-2032)

Figure 77. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share Forecast by Application (2027-2032)

Figure 78. GCC Countries Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 (\$ millions)

I would like to order

Product name: Global Circulating Tumour DNA (ctDNA) Testing Market Growth (Status and Outlook) 2026-2032

Product link: <https://marketpublishers.com/r/G85406982B78EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G85406982B78EN.html>